Retatrutide (also designated LY3437943) is a novel triple receptor agonist peptide that simultaneously targets glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triagonist mechanism distinguishes it from dual agonists such as tirzepatide, offering researchers a unique tool for investigating the interplay between multiple incretin and glucagon pathways in metabolic regulation.
In preclinical and early clinical research, retatrutide has demonstrated substantial effects on body weight reduction, glycaemic control, and energy expenditure. The glucagon receptor component is of particular interest to researchers studying hepatic glucose output, lipid metabolism, and thermogenesis, whilst the GLP-1 and GIP components contribute to insulin secretion modulation and appetite regulation pathways.
This 40mg research vial is supplied as a lyophilised powder with a purity of >98% as verified by HPLC analysis. Molecular formula: C₂₂₂H₃₄₀N₅₆O₆₆S. Molecular weight: approximately 4963.5 g/mol. CAS number: 2381320-10-9.
For optimal stability, store lyophilised product at -20°C, protected from light and moisture. Once reconstituted, store at 4°C and use within 14 days.
Molecular Formula
C₂₂₂H₃₄₀N₅₆O₆₆S
Molecular Weight
4963.5 g/mol
Purity
>98%
CAS Number
2381320-10-9
Form
Lyophilised Powder
Research Applications
Metabolic disorder research, Obesity and adiposity studies, Glycaemic regulation, Hepatic lipid metabolism, Energy expenditure and thermogenesis, Incretin pathway research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.